NCT05230810View on ClinicalTrials.gov

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

August 30, 2024

Study Completion Date

June 30, 2025

Conditions
HER2-positive Metastatic Breast Cancer
Interventions
DRUG

Alpelisib

Orally twice a day

DRUG

Tucatinib

Orally once a day

DRUG

Fulvestrant

"500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"

Trial Locations (4)

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

70112

RECRUITING

Louisiana State University Health Sciences Center, New Orleans

80045

RECRUITING

University of Colorado Cancer Center, Aurora

80528

RECRUITING

Cancer Care & Hematology-Fort Collins, Fort Collins

Sponsors

Lead Sponsor

Criterium, Inc.

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

lead

Criterium, Inc.

INDUSTRY

NCT05230810 - Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | Biotech Hunter | Biotech Hunter